Nanjing King-Friend Biochemical PharmaceuticalLtd (603707) Stock Overview
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
603707 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.64 |
| 52 Week High | CN¥12.27 |
| 52 Week Low | CN¥6.72 |
| Beta | 0.42 |
| 1 Month Change | -3.66% |
| 3 Month Change | -20.99% |
| 1 Year Change | -31.17% |
| 3 Year Change | -42.34% |
| 5 Year Change | -66.30% |
| Change since IPO | 173.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| 603707 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 11.7% | 13.5% | 0.4% |
| 1Y | -31.2% | -6.4% | 27.7% |
Return vs Industry: 603707 underperformed the CN Pharmaceuticals industry which returned -6.4% over the past year.
Return vs Market: 603707 underperformed the CN Market which returned 27.7% over the past year.
Price Volatility
| 603707 volatility | |
|---|---|
| 603707 Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in CN Market | 11.1% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 603707 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603707's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,558 | Tang Yongqun | www.nkf-pharma.com |
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. It also provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium besylate, cisatracurium, calcium folinate, doxorubicin, milrinone, bleomycin, carboplatin, cytarabine, topotecan hydrochloride, phenylephrine hydrochloride, ganirelix acetate, furosemide, glycopyrrolate, neostigmine methylsulfate, succinylcholine chloride, reganosin, isoflurane blue, clofarabine, haloperidol decanoate, busulfan, gemcitabine hydrochloride, dexmedetomidine hydrochloride, nelarabine, rocuronium bromide, zoledronic acid, bupivacaine hydrochloride, plerixafor, eptifibatide, fondaparinux sodium, docetaxel, fluorouracil, palonosetron hydrochloride, oxaliplatin, fulvestrant, and adalimumab injections.
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Fundamentals Summary
| 603707 fundamental statistics | |
|---|---|
| Market cap | CN¥12.33b |
| Earnings (TTM) | CN¥585.83m |
| Revenue (TTM) | CN¥4.03b |
Is 603707 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603707 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.03b |
| Cost of Revenue | CN¥2.29b |
| Gross Profit | CN¥1.75b |
| Other Expenses | CN¥1.16b |
| Earnings | CN¥585.83m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 29, 2026
| Earnings per share (EPS) | 0.36 |
| Gross Margin | 43.33% |
| Net Profit Margin | 14.52% |
| Debt/Equity Ratio | 37.5% |
How did 603707 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/04 19:05 |
| End of Day Share Price | 2026/07/03 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Zhu Chen | Citic Securities Co., Ltd. |
| Wen Dai | Huatai Research |